Questions regarding the safety and duration of immunity following live yellow fever vaccination

Expert Review of Vaccines

Volumn 15, Issue 12, 2016, Pages 1519-1533

  Amanna, Ian J ^a   Slifka, Mark K ^b  

^a Najit Technologies Inc   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

antibody duration; flaviviruses; immunity; neurotropic; vaccination; viscerotropic; Yellow fever virus

Indexed keywords

LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; YELLOW FEVER VACCINE;

ANAPHYLAXIS; ANTIBODY RESPONSE; COST BENEFIT ANALYSIS; DRUG SAFETY; HUMAN; MARKET; MEMORY T LYMPHOCYTE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REINFECTION; REVIEW; RISK BENEFIT ANALYSIS; VACCINATION; VISCERAL PROLAPSE; YELLOW FEVER; IMMUNOLOGY; SECONDARY IMMUNIZATION; TIME FACTOR; TREATMENT FAILURE; UTILIZATION;

HUMANS; IMMUNIZATION, SECONDARY; TIME FACTORS; TREATMENT FAILURE; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84996560239     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2016.1198259     Document Type: Review

References (114)

1. Russell MN, Cetron MS, Eidex RB., The US-certified yellow fever vaccination center registry:a tool for travelers, state health departments, and vaccine providers. J Travel Med. 2006;13(1):48–49.
2. Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2015;64:160–173.
3. Camara FP, De Carvalho LM, Gomes AL. Demographic profile of sylvatic yellow fever in Brazil from 1973 to 2008. Trans R Soc Trop Med Hyg. 2013;107(5):324–327.•• Describes 831 cases of yellow fever in Brazil with 459 (55%) of the patients described as having a history of YFV-17D vaccination. This indicates that YFV-17D vaccine failures are more common than previously realized.
4. Collaborative Group for Studies on Yellow Fever Vaccines. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. 2015;110(6):771–780.
5. Camacho LA, Freire Mda S, Leal Mda L, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines:a randomized trial. Rev Saude Publica. 2004;38(5):671–678.
6. Nascimento Silva JR, Camacho LA, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29(37):6327–6334.
7. Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012;11(4):427–448.
8. Engel AR, Vasconcelos PF, McArthur MA, et al. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine. 2006;24(15):2803–2809.
9. World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper–June 2013. Wkly Epidemiol Record. 2013;88(27):269–283.
10. World Health Organization. Background paper on yellow fever vaccine. In:SAGE Working Group, editor. Vaccine position papers. Geneva (Switzerland):SAGE Working Group; 2013.
11. Centers for Disease Control and Prevention. Grading of recommendations, assessment, development, and evaluation (GRADE) for yellow fever vaccine booster doses. In:US Department of Health and Human Services, CDC, editor. GRADE evidence tables - recommendations in MMWR. Atlanta (GA); 2015.
12. Staples JE, Bocchini JA, Jr, Rubin L, et al. Yellow fever vaccine booster doses:recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):647–650.• An updated ACIP recommendation for YF-17D vaccination that includes the discontinuation of booster doses for most travelers, although individuals at high exposure risk should continue to get vaccinated at least every 10 years.
13. Collaborative Group for Studies on Yellow Fever Vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014;32(39):4977–4984.
14. Patel D, Simons H. Yellow fever vaccination:is one dose always enough? Travel Med Infect Dis. 2013;11(5):266–273.
15. Grobusch MP, Goorhuis A, Wieten RW, et al. Yellow fever revaccination guidelines change–a decision too feverish? Clin Microbiol Infect. 2013;19(10):885–886.
16. Domingues CMAS. Parecer No. 05/CGPNI/DEVIT/SVS/MS. Recomendações de vacinação contra febre amarela para viajantes, após a declaração da Organização Mundial da Saúde [Recommendations of yellow fever vaccination for travelers, following a statement of the World Health Organization]. Brasília:Ministério da Saúde, Departamento de Vigilância das Doenças Transmissíveis; 2015.
17. Maranhão AGK. Nota informativa No. 143/CGPNI/DEVIT/SVS/MS. Recomendações da vacinação contra febre amarela, após a declaração da Organização Mundial da Saúde [Recommendations of vaccination against yellow fever, following a statement of the World Health Organization]. Brasília:Ministério da Saúde, Departamento de Vigilância das Doenças Transmissíveis; 2014.
18. Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med. 2006;203(2):413–424.
19. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116–125.
20. Pulendran B. Learning immunology from the yellow fever vaccine:innate immunity to systems vaccinology. Nat Rev Immunol. 2009;9(10):741–747.
21. Kohler S, Bethke N, Bothe M, et al. The early cellular signatures of protective immunity induced by live viral vaccination. Eur J Immunol. 2012;42(9):2363–2373.
22. Miller JD, Van Der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710–722.
23. Akondy RS, Monson ND, Miller JD, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919–7930.
24. James EA, LaFond RE, Gates TJ, et al. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol. 2013;87(23):12794–12804.
25. Blom K, Braun M, Ivarsson MA, et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol. 2013;190(5):2150–2158.
26. Schulz AR, Malzer JN, Domingo C, et al. Low thymic activity and dendritic cell numbers are associated with the immune response to primary viral infection in elderly humans. J Immunol. 2015;195:4699–4711.
27. Niedrig M, Lademann M, Emmerich P, et al. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays:neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health. 1999;4(12):867–871.• This study shows the durability of antibody responses in YFV-17D-vaccinated individuals for up to 35 years after vaccination.
28. Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59(6):895–900.
29. Monath TP, Gershman M, Staples JE, et al. Yellow fever vaccine. In:Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia (PA):Saunders/Elsevier; 2013. p. 870–968.• This chapter provides a comprehensive description of yellow fever disease in addition to in-depth analysis of the safety and efficacy of yellow fever vaccination.
30. Reinhardt B, Jaspert R, Niedrig M, et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D:a model of human flavivirus infection. J Med Virol. 1998;56(2):159–167.
31. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine:phase I clinical trial for safety and immunogenicity:effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006;2(2):60–67.
32. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax:recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002;20(7–8):1004–1018.
33. Amanna IJ, Slifka MK. Wanted, dead or alive:new viral vaccines. Antiviral Res. 2009;84(2):119–130.
34. Slifka MK. Vaccine-mediated immunity against dengue and the potential for long-term protection against disease. Front Immunol. 2014;5(195):1–7.
35. Sawyer WA. Persistence of yellow fever immunity. J Prev Med. 1931;5:413–428.• The first demonstration that neutralizing serum antibodies could protect against lethal yellow fever.
36. Thibodeaux BA, Garbino NC, Liss NM, et al. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res. 2012;94(1):1–8.
37. Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011;29(35):6008–6016.
38. Mason RA, Tauraso NM, Spertzel RO, et al. Yellow fever vaccine:direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol. 1973;25(4):538–544.• This study determined that 0.7 LNI is the correlate of protective immunity in rhesus macaques after YFV-17D vaccination.
39. Dick GW, Gee FL. Immunity to yellow fever nine years after vaccination with 17D vaccine. Trans R Soc Trop Med Hyg. 1952;46(4):449–458.
40. De Melo AB, Da Silva Mda P, Magalhaes MC, et al. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg. 2011;85:739–747.
41. Machado VW, Vasconcelos PF, Silva EV, et al. Serologic assessment of yellow fever immunity in the rural population of a yellow fever-endemic area in Central Brazil. Rev Soc Bras Med Trop. 2013;46(2):166–171.
42. Rosenzweig EC, Babione RW, Wisseman CL, Jr. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg. 1963;12:230–235.
43. Courtois G. [Duration of immunity after yellow fever vaccination]. Ann Soc Belg Med Trop. 1954;34(1):9–12.
44. Groot H, Riberiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ. 1962;27:699–707.
45. Gomez SY, Ocazionez RE. Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue. Rev Salud Publica (Bogota). 2008;10(5):796–807.
46. Coulange Bodilis H, Benabdelmoumen G, Gergely A, et al. Long term persistence of yellow fever neutralising antibodies in elderly persons. Bull Soc Pathol Exot. 2011;104(4):260–265.
47. Hepburn MJ, Kortepeter MG, Pittman PR, et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine. 2006;24:2843–2849.• This study of 1029 laboratory researchers describes a rapid decline in neutralizing antibodies, particularly in the first 1–3 years after booster vaccination.
48. Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med. 2005;11:740–747.
49. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nature Medicine. 2003;9(9):1131–1137.
50. Crotty S, Felgner P, Davies H, et al. Cutting edge:long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003;171(10):4969–4973.
51. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903–1915.
52. Frey SE, Wald A, Edupuganti S, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects. Vaccine. 2015;33(39):5225–5234.
53. Von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine. 2010;28(5):1209–1216.
54. Beck AS, Barrett AD. Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines. 2015;14(11):1479–1492.
55. Doblas A, Domingo C, Bae HG, et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol. 2006;36:156–158.
56. Akondy RS, Johnson PL, Nakaya HI, et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci U S A. 2015;112(10):3050–3055.
57. Domingo C, Yactayo S, Agbenu E, et al. Detection of yellow fever 17D genome in urine. J Clin Microbiol. 2011;49(2):760–762.
58. Hammarlund E, Lewis MW, Hanifin JM, et al. Traditional smallpox vaccination with reduced risk of inadvertent contact spread by administration of povidone iodine ointment. Vaccine. 2008;26(3):430–439.
59. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002;66(5):533–541.
60. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48:659–666.
61. Monath TP. Dengue and yellow fever–challenges for the development and use of vaccines. N Engl J Med. 2007;357:2222–2225.
62. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077–6082.
63. Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril®:a 17-year review. Expert Rev Vaccines. 2013;12(11):1351–1368.
64. Breugelmans JG, Lewis RF, Agbenu E, et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013;31(14):1819–1829.
65. Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine:an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23:3256–3263.
66. Schumacher Z, Bourquin C, Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland–1991–2001. Vaccine. 2010;28:4059–4064.
67. Wattigney WA, Mootrey GT, Braun MM, et al. Surveillance for poliovirus vaccine adverse events, 1991 to 1998:impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics. 2001;107(5):E83.
68. Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J. 2001;20(4):410–416.
69. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344(8):564–572.
70. Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol. 1999;103:698–701.
71. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815–820.
72. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine. 2004;22(17–18):2103–2105.
73. Fernandes GC, Camacho LA, Sa Carvalho M, et al. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999–2005. Vaccine. 2007;25:3124–3128.
74. Guimard T, Minjolle S, Polard E, et al. Short report:Incidence of yellow fever vaccine-associated neurotropic disease. Am J Trop Med Hyg. 2009;81:1141–1143.
75. Prevots DR, Sutter RW, Strebel PM, et al. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med. 1994;148(5):479–485.
76. Hao L, Toyokawa S, Kobayashi Y. Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. Jpn J Infect Dis. 2008;61(2):100–103.
77. Whittembury A, Ramirez G, Hernandez H, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009;27:5974–5981.
78. Miller ER, Moro PL, Cano M, et al. Deaths following vaccination:what does the evidence show? Vaccine. 2015;33(29):3288–3292.
79. Zanardi LR, Haber P, Mootrey GT, et al. Intussusception among recipients of rotavirus vaccine:reports to the vaccine adverse event reporting system. Pediatrics. 2001;107(6):E97.
80. Biscayart C, Carrega ME, Sagradini S, et al. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina. Vaccine. 2014;32(11):1266–1272.
81. Fitzner J, Coulibaly D, Kouadio DE, et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine. 2004;23:156–162.
82. Stuart G. Reactions following vaccination against yellow fever. In:World Health Organization, editor. Yellow fever vaccination. Geneva (Switzerland):WHO; 1956. p. 143– 189.
83. YF-VAX® Package Insert. Swiftwater (PA):Sanofi Pasteur; 2013. Rev. 2013 May2.
84. Staples JE, Gershman M, Fischer M. Yellow fever vaccine:recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–27.
85. Sencer DJ, Langmuir AD, Kokko UP, et al. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. Jama. 1966;198(6):671–672.
86. Jennings AD, Gibson CA, Miller BR, et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis. 1994;169(3):512–518.
87. Martins Rde M, Pavao AL, De Oliveira PM, et al. Adverse events following yellow fever immunization:report and analysis of 67 neurological cases in Brazil. Vaccine. 2014;32(49):6676–6682.
88. Martins Rde M, Maia Mde L, Dos Santos EM, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Proc Vaccinol. 2010;2:178–183.
89. Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil:a report of two cases. Lancet. 2001;358:91–97.
90. Rafferty E, Duclos P, Yactayo S, et al. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly:a systematic review. Vaccine. 2013;31(49):5798–5805.
91. Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32(44):5769–5775.
92. Monath TP. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg. 2010;82:919–921.
93. Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events:systematic review. Vaccine. 2011;29:4544–4555.
94. Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002;51(RR–17):1–11.
95. Fox JP, Lennette EH, Manso C, et al. Encephalitis in man following vaccination with 17D yellow fever virus. Amer J Hyg. 1942;36(2):117–142.
96. WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. In:World Health Organization, editor. WHO expert committee on biological standardization. Geneva (Switzerland):WHO; 2012. p. 241–314.
97. Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States:introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR–3):1–25.
98. World Health Organization. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus. Bull World Health Organ. 1969;40(6):925–945.
99. Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR–5):1–22.
100. Walton LR, Orenstein WA, Pickering LK. Lessons learned from making and implementing vaccine recommendations in the U.S. Vaccine. 2015;33(Suppl 4):D78–82.
101. Hayes EB. Is it time for a new yellow fever vaccine? Vaccine. 2010;28(51):8073–8076.
102. Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002;34:1369–1378.
103. Plotkin SL, Plotkin SA. A short history of vaccination. In:Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia (PA):Saunders/Elsevier; 2008. p. 1–16.
104. Black S. The role of health economic analyses in vaccine decision making. Vaccine. 2013;31(51):6046–6049.
105. Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal. 2006;26:1423–1440.
106. Miller MA, Sutter RW, Strebel PM, et al. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276(12):967–971.
107. Monath TP, Lee CK, Julander JG, et al. Inactivated yellow fever 17D vaccine:development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010;28:3827–3840.
108. Amanna IJ, Raue HP, Slifka MK. Development of a new hydrogen peroxide-based vaccine platform. Nat Med. 2012;18(6):974–979.
109. Gaspar LP, Mendes YS, Yamamura AM, et al. Pressure-inactivated yellow fever 17DD virus:implications for vaccine development. J Virol Methods. 2008;150:57–62.
110. Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011;364(14):1326–1333.
111. World Health Organization. Immunization, Vaccines and Biologicals - African Region. Geneva; 2015. Available from: http://www.who.int/immunization/monitoring_surveillance/data/AFR/en/
112. Slifka MK, Amanna I. How advances in immunology provide insight into improving vaccine efficacy. Vaccine. 2014;32(25):2948–2957.
113. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013;6(11):1242–1250.
114. Bovier PA, Bock J, Ebengo TF, et al. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol. 2010;82(10):1629–1634.